Balance Sheet StrengthA high equity ratio and low leverage provide durable financial resilience, enabling the company to fund R&D and commercialization without immediate reliance on external debt. This capital structure supports multi-quarter product development and absorbs volatility in operating results.

Improving Operating MarginsRising EBIT/EBITDA margins indicate the business is converting revenue into operating profitability more efficiently, a lasting sign of scalable operations and better cost control. Improved margins enhance reinvestment capacity and reduce sensitivity to revenue swings over months.

High Gross Profit MarginsSustainably high gross margins imply attractive unit economics for core products, giving pricing flexibility and margin buffer as the company scales. Strong product-level profitability supports long-term commercial viability even if SG&A increases during expansion.

Bears Say

Weak Cash GenerationPersistent negative operating and free cash flow limits internal funding for R&D, regulatory work, and commercialization, forcing reliance on external financing or equity. Over several quarters this can constrain strategic initiatives and increase financial risk despite low leverage.

Revenue VolatilityLarge swings in year-over-year revenue indicate uneven demand or lumpy recognition (e.g., one-off deals). This volatility reduces forecast reliability and complicates capacity planning, partner negotiations, and timing of commercialization investments over the medium term.

Limited Operational ScaleAn extremely small workforce constrains regulatory submissions, commercial rollouts, and partner management, increasing execution risk. Growth or scaling will likely require rapid hiring or outsourcing, which can raise costs and slow time-to-market over several quarters.

Tsubota Laboratory Incorporated News

Tsubota Laboratory Swings to Heavy Loss as Revenue Plunges, Forecasts Deep Full-Year Deficit

Tsubota Laboratory Incorporated ( ($JP:4890) ) has shared an update. Tsubota Laboratory reported a sharp deterioration in non-consolidated...

26d ago

4890

Tsubota Laboratory’s Interim Financial Results Highlight Sustainable Growth Strategy

Tsubota Laboratory Incorporated ( ($JP:4890) ) has provided an announcement. Tsubota Laboratory Incorporated has announced its interim financial...

4M ago

4890

Tsubota Laboratory Reports Significant Revenue Decline and Net Loss

Tsubota Laboratory Incorporated ( ($JP:4890) ) has shared an update. Tsubota Laboratory Incorporated reported a significant decline in...

4M ago

4890

Tsubota Laboratory Reports First Quarter Losses Amidst Sales Decline

An update from Tsubota Laboratory Incorporated ( ($JP:4890) ) is now available. Tsubota Laboratory Incorporated reported a decrease...

7M ago

4890

Tsubota Laboratory Reports Strong Financial Recovery in FY2025

The latest announcement is out from Tsubota Laboratory Incorporated ( ($JP:4890) ). Tsubota Laboratory, Inc. reported significant financial...

10M ago

4890

Tsubota Laboratory’s Impressive Financial Turnaround in 2024

Tsubota Laboratory Incorporated (JP:4890) has released an update. Tsubota Laboratory, Inc. reports a significant increase in net sales...

1y ago

4890

4890 FAQ

What was Tsubota Laboratory Incorporated’s price range in the past 12 months?

Tsubota Laboratory Incorporated lowest stock price was ¥251.00 and its highest was ¥460.00 in the past 12 months.

What is Tsubota Laboratory Incorporated’s market cap?

Tsubota Laboratory Incorporated’s market cap is ¥7.82B.

When is Tsubota Laboratory Incorporated’s upcoming earnings report date?

Tsubota Laboratory Incorporated’s upcoming earnings report date is May 18, 2026 which is in 68 days.

How were Tsubota Laboratory Incorporated’s earnings last quarter?

Tsubota Laboratory Incorporated released its earnings results on Feb 13, 2026. The company reported -¥7.22 earnings per share for the quarter, missing the consensus estimate of N/A by -¥7.22.

Is Tsubota Laboratory Incorporated overvalued?

According to Wall Street analysts Tsubota Laboratory Incorporated’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Tsubota Laboratory Incorporated pay dividends?

Tsubota Laboratory Incorporated does not currently pay dividends.

What is Tsubota Laboratory Incorporated’s EPS estimate?

Tsubota Laboratory Incorporated’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Tsubota Laboratory Incorporated have?

Tsubota Laboratory Incorporated has 25,794,300 shares outstanding.

What happened to Tsubota Laboratory Incorporated’s price movement after its last earnings report?

Tsubota Laboratory Incorporated reported an EPS of -¥7.22 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -3.534%.

Which hedge fund is a major shareholder of Tsubota Laboratory Incorporated?

Currently, no hedge funds are holding shares in JP:4890

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Tsubota Laboratory Incorporated

Tsubota Laboratory Incorporated engages in the research and development of pharmaceuticals and medical devices for the treatment of myopia, dry eyes, and presbyopia. The company was incorporated in 2012 and is based in Tokyo, Japan.